Bibliography
- World Health Organisation: The World Health Report 2004 – changing history. Geneva: World Health Organisation; 2004
- Martin SJ, Sahloff EG, Close SJ. Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections. Expert Opin Pharmacother 2002;3:1251-66
- Blondeau J. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 1999;43:1-11
- Miravittles M. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother 2005;6:283-93
- Aliyu ZY, Aliyu MH, Mccormick K. Determinants for hospitalization in ‘low-risk’ community acquired pneumonia. BMC Infect Dis 2003;3:11
- Talwar A, Lee H, Fein A. Community-acquired pneumonia: what is relevant and what is not? Curr Opin Pulm Med 2007;13:177-85
- Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics 2002;20:513-28
- Niederman MS. Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin. Clin Infect Dis 2005;41(Suppl 2):158-66
- American Thoracic Society and European Respiratory Society: standards for the diagnosis and management of patients with COPD. New York, NY: American Thoracic Society and European Respiratory Society, 2004. Available from: http://www.thoracic.org/sections/copd/resources/copddoc.pdf [Last accessed 28 February 2008]
- Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204
- Wilson R, Allegra L, Huchon G, et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004;125:953-64
- Klossek JM, Federspil P. Update on treatment guidelines for acute bacterial sinusitis. Int J Clin Pract 2005;59:230-8
- Lau J, Zucker D, Engels EA, et al. Diagnosis and treatment of acute bacterial rhinosinusitis. Rockville MD: Agency for Health Care Policy and Research; 1999
- Klossek JM, Siegert R, Nikolaidis P, et al. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. J Laryngol Otol 2003;117:43-51
- Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Respir Med 2000;94:337-44
- Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford University Press: Oxford; 2005
- Martin M, Quilici S, File T, et al. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother 2007;59:977-89
- Martin M, Moore L, Quilici S, et al. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. Curr Med Res Opin 2008;24:737-51
- Sabes-Figuera R, Segu JL, Puig-Junoy J, Torres A. Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia. Eur J Health Econ 2008;9:23-32
- Jones ME, Blosser-Middleton RS, Critchley IA, et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 – 2001. Clin Microbiol Infect 2003;9:590-9
- Valcke Y. CAP guidelines: why differences between Belgian and American/Canadian guidelines? Louvain: Université Catholique de Louvain, 2001. Available from: http://www.farm.ucl.ac.be/seminfec//Atelier-Mandell-23-11-01/Valcke/Valcke.pdf [Last accessed 25 February 2008]
- Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998 – 2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-46
- Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003;124:526-35
- Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005;128:2238-46
- Lloyd A, Battleman D, Choudhri S, et al. Cost-effectiveness analysis of intravenous moxifloxacin compared to levofloxacin in hospitalized elderly patients with community-acquired pneumonia. Abstract presented at the Sixth European Congress of Clinical Microbiology and Infectious Diseases; 2006 April 1 – 4; Nice, France
- Davis SL, Delgado G, Mckinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis 2005;41(Suppl 2):136-43
- Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996;42:410-25
- Llor C, Naberan K, Cots JM, et al. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care. Int J Clin Pract 2004;58:937-44
- Miravittles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur Respir J 2001;17:928-33
- Miravitlles M, Llor C, Naberan K, et al. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med 2005;99:955-65
- Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 2002;49:897-903
- Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999;43(Suppl B):83-90
- Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004;26:940-50
- Keating KN, Friedman HS, Perfetto EM. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges. Curr Med Res Opin 2006;22:327-33
- Torrance G, Walker V, Grossman R, et al. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 1999;16:499-520
- Spiritus E. Antibiotic usage for respiratory tract infections in an era of rising resistance and increased cost pressure. Am J Manag Care 2000;23(Suppl 1):1216-21
- File TM Jr. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 2004;117(Suppl 3A):39-50
- Lonks JR, Garau J, Medeiros AA. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J Antimicrob Chemother 2002;50(Suppl S2):87-92
- Welte T, Marre R, Suttrop N. What is new in the treatment of community-acquired pneumonia? Med Klin (Munich) 2006;101:313-20
- Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-80
- Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-76
- Pallares R, Fenoll A, Linares J; The Spanish Pneumococcal Infection Study Network. The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones. Int J Antimicrob Agents 2003;22(Suppl 1):15-24
- Simoens S, Verhaegen J, Laekeman G, Peetermans WE. Treating respiratory tract infections in ambulatory care in Belgium: fluoroquinolone consumption and resistance development. Int J Antimicrob Agents 2005;26:62-8